Figure 1. Western blot detection of EpoR with C-20 anti-EpoR antibodies.
Whole-cell extracts were prepared from unstimulated UT-7 cells (lane 1), Mo7E cells (lane 2), UT-7 cells stimulated for 10 minutes (lanes 3 and 10) or for 90 minutes (lane 4) with Epo, UT-7 cells incubated for 6 hours with cycloheximide (lane 5), and EpoR-transfected BaF3 cells stimulated for 10 minutes with Epo (lane 11). UT-7 cells stimulated for 10 minutes with Epo or biotinylated Epo (lane 6) were solubilized as previously described, 4 and cell extracts were precipitated with streptavidin (lane 6), a laboratory-made anti-GST-EpoR antibody (lane 7), anti-GST antibodies (lane 8), and anti-Epo antibodies (lane 9). Portions corresponding to 250 ϫ 10 3 cells (whole-cell extracts) or to 10 6 cells (precipitations) were separated on 8.5% (A-B,D) or 10% polyacrylamide gels (C) and transferred to nitrocellulose and analyzed by WB using Santa Cruz Biotechnology C-20 antibodies (catalog no. SC-695) batch K200 (A left, B-D) or batch B2105 (A right). Images were recorded on a LAS 3000 FujiFilm camera. 
Response:

Anti-Epo receptor antibodies do not predict Epo receptor expression
In this issue, Verdier et al comment on our recent publication, concluding that some anti-EpoR antibodies have limited utility for detecting EpoR expression. 1 We reported that the C-20 anti-EpoR antibody from Santa Cruz Biotechnology (Santa Cruz, CA) detected 5 protein bands in UT-7/Epo cells including 59-kDa and 66-kDa proteins. Using both direct and indirect methods, we showed that the 59-kDa protein, not the 66-kDa protein, is EpoR: (1) the 59-kDa protein migrated similarly to recombinant, FLAGtagged, full-length EpoR; (2) the 59-kDa protein levels decreased following EPOR shRNA treatment of cells, whereas 66-kDa protein levels remained unchanged; (3) the 59-kDa protein was absent in EPOR-knockout fetal liver but present in wild-type fetal liver; (4) C-20 immunoprecipitated the 59-kDa protein, not the 66-kDa protein, from UT-7/Epo cells (the immunocomplexed 59-kDa protein was detected by 2 other anti-EpoR antibodies, 07-311 and M-20); (5) the 59-kDa, not the 66-kDa, protein bands contained EpoR peptide sequences; and (6) peptides derived from heat-shock proteins specifically inhibited C-20 binding to the 66-kDa protein.
Agreeing that many antibodies are unsuitable for detecting EpoR, the authors also do not challenge our conclusion that C-20 should not be used for immunohistochemistry. However, they disagree about the utility of C-20 for detecting EpoR proteins in Western blots and that the apparent molecular mass of EpoR is approximately 59 kDa, not 66/78 kDa as described in the product information sheet provided by Santa Cruz.
Verdier et al claimed that 3 protein bands larger than 59 kDa (64, 67.6, and 69.5 kDa) detected in UT-7 cells by C-20 were different forms of EpoR, based on indirect methods. First, they showed that the 64-kDa protein was not detected by C-20 in EpoR-negative Mo7E cells, although an approximately 68-kDa protein was detected in the same cells. Second, they showed that the levels of these proteins were altered following treatment with cycloheximide or stimulation with Epo. However, neither agent necessarily selectively alters EpoR levels. Third, they used an in-house anti-EpoR antibody (C-236), biotinylated Epo/streptavidin, and an anti-Epo antibody to immunoprecipitate the putative EpoR proteins, but each yielded different protein patterns. For example, 2 proteins were immunoprecipitated by C-236 and only one by biotinylated Epo/streptavidin or the anti-Epo antibody. Furthermore, when probed with a second batch of C-20 (lot B2105), the negative control anti-GST antibody appeared to precipitate the same 2 putative EpoR proteins as C-236. Finally, they showed a predominant 64-kDa protein in BaF3 cells transfected with EPOR; expression of the larger 67.6-and 69.5-kDa proteins did not increase in this experiment. Based on their results, we do not believe that Verdier et al have adequately demonstrated that the larger proteins detected by C-20 are EpoR. A possible explanation for the discrepancies between the 2 studies is that the 64-kDa protein detected by Verdier et al is the same as the 59-kDa EpoR protein we report, whereas the larger proteins are non-EpoR cross-reacting proteins. The reported size difference (59 vs 64 kDa) may be a consequence of different conditions used to resolve the proteins or the use of different marker proteins to estimate size. To the editor:
Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate
In a recent article, Elliott et al 1 question the specificity of commercially available antibodies against the erythropoietin receptor (EpoR) and thus the validity of an increasing number of studies showing expression of functional EpoR in many nonhematopoietic tissues including most solid cancers. [2] [3] [4] [5] [6] It is well known that antibody qualities are quite variable. The effort of Elliott et al 1 to thoroughly test the available EpoR antibodies should therefore be appreciated, because the authors could eventually have contributed to this field of research. However, a closer look at their study reveals severe methodological issues. First, Elliott et al 1 used an expression construct for EpoR that has not been verified in this study. Unfortunately, the detected band was not subjected to liquid chromatography coupled to mass spectrometry (LC-MS), functional integrity of the expressed protein was not demonstrated, and it is therefore unclear if the expression plasmid codes for a functional human EpoR. Second, EpoR undergoes posttranslational modification and functional EpoR has a size between 66 and 78 kDa. A soluble form of EpoR and a truncated form of this receptor can be detected at lower molecular weight. The 59-kDa band detected by Elliott et al 1 is most likely physiologically irrelevant and raises the question why proteins derived from their expression plasmid are not processed into active receptors. Third, after ligand binding, EpoR is internalized and degraded. The cancer lines used by Elliott et al 1 show varying levels of EpoR surface levels under standard culture conditions. EpoR is usually detectable only after serum starvation, and lack of EpoR expression in these cells under the conditions chosen is no surprise to anyone in this research field. In addition, the C20 antibody was used at 1.32 g/mL, whereas the manufacturer recommends 0.1 to 1.0 g/mL. Culture conditions, which
